Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4793572
Max Phase: Preclinical
Molecular Formula: C87H109Cl2N37O18
Molecular Weight: 1959.05
Molecule Type: Unknown
Associated Items:
ID: ALA4793572
Max Phase: Preclinical
Molecular Formula: C87H109Cl2N37O18
Molecular Weight: 1959.05
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)Nc1cn(C)c(C(=O)Nc2cn(C)c(C(=O)Nc3cc(C(=O)Nc4cn(C)c(C(=O)NCCC(=O)Nc5cn(C)c(C(=O)Nc6cn(C)c(C(=O)NCC[C@@H](N)C(=O)Nc7cc(C(=O)Nc8cc(C(=O)NC[C@@H](O)CC(=O)Nc9cc(C(=O)Nc%10cn(C)c(C(=O)Nc%11cc(C(=O)Nc%12cc(C(=O)NCCC(=O)NCCCN(C)C)n(C)c%12)n(C)c%11)n%10)n(C)c9)n(C)c8)n(C)c7)n6)n5)n4)n(C)c3)n2)n1.Cl.Cl
Standard InChI: InChI=1S/C87H107N37O18.2ClH/c1-45(125)94-60-39-121(12)73(102-60)86(141)111-65-44-124(15)72(107-65)85(140)100-51-30-59(118(9)38-51)81(136)108-62-41-119(10)70(104-62)83(138)92-23-19-67(128)101-61-40-122(13)74(103-61)87(142)110-64-43-120(11)69(105-64)82(137)91-21-17-53(88)75(130)96-47-28-56(116(7)34-47)78(133)98-49-27-55(114(5)36-49)77(132)93-32-52(126)31-68(129)95-46-25-58(115(6)33-46)80(135)109-63-42-123(14)71(106-63)84(139)99-50-29-57(117(8)37-50)79(134)97-48-26-54(113(4)35-48)76(131)90-22-18-66(127)89-20-16-24-112(2)3;;/h25-30,33-44,52-53,126H,16-24,31-32,88H2,1-15H3,(H,89,127)(H,90,131)(H,91,137)(H,92,138)(H,93,132)(H,94,125)(H,95,129)(H,96,130)(H,97,134)(H,98,133)(H,99,139)(H,100,140)(H,101,128)(H,108,136)(H,109,135)(H,110,142)(H,111,141);2*1H/t52-,53+;;/m0../s1
Standard InChI Key: OEALSNYMNYYNMP-QQXZZZDISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1959.05 | Molecular Weight (Monoisotopic): 1957.8595 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Zhang M,Liang J,Jiang SK,Xu L,Wu YL,Awadasseid A,Zhao XY,Xiong XQ,Sugiyama H,Zhang W. (2020) Design, synthesis and anti-cancer activity of pyrrole-imidazole polyamides through target-downregulation of c-kit gene expression., 207 [PMID:32866755] [10.1016/j.ejmech.2020.112704] |
Source(1):